Evidence Level
Epigallocatechin Gallate (EGCG), a prominent polyphenol found in green tea and matcha, has been extensively studied for its potential health benefits. A meta-analysis by Huang et al. (2014) highlighted EGCG's anti-obesity effects through human studies and molecular mechanisms, while Kuriyama et al. (2006) demonstrated a reduction in cardiovascular mortality among over 40,000 Japanese adults who consumed green tea regularly.
Recent research underscores EGCG's role in cancer prevention. Zhang et al. (2025) conducted a systematic review of 43 studies, including 7 RCTs and 36 cohort studies, which found that green tea and EGCG significantly reduced the risk of several cancers, particularly prostate, oral, gallbladder, and hematological cancers. Additionally, Saadh et al. (2025) analyzed 41 RCTs and reported modest reductions in fasting blood glucose, HbA1c, and HOMA-IR with EGCG supplementation, though effects on fasting insulin were minimal.
However, hepatotoxicity risks have been associated with high-dose EGCG consumption. Mazzanti et al. (2015) reviewed case reports and advisories, linking fasted, high-dose EGCG to liver injury. Regulatory guidelines recommend consuming EGCG with food and limiting daily intake to below 800mg. Matcha-derived EGCG may offer a safer alternative due to the presence of protective compounds.
In summary, EGCG exhibits promising potential in cancer prevention and metabolic benefits but necessitates cautious use to mitigate hepatotoxicity risks.